Stock comparison
United Therapeutics
Vericel
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
VCEL
Vericel
Market cap
$1.77B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | UTHR | VCEL | Winner |
|---|---|---|---|
| Warren Buffett | 71B | 52D | UTHR |
| Benjamin Graham | 76B | 69D | UTHR |
| Philip Fisher | 76B | 57C | UTHR |
| Peter Lynch | 62C | 45D | UTHR |
| Joel Greenblatt | 46D | 44D | UTHR |
| Charlie Munger | 64C | 43D | UTHR |
| Terry Smith | 64C | 52D | UTHR |
Side-by-side metrics
| Metric | UTHR | VCEL |
|---|---|---|
| Market cap | $24.13B | $1.77B |
| P/E (TTM) | 19.2x | 82.5x |
| EV/EBIT | 15.2x | 159.9x |
| ROIC (TTM) | 18.81% | 3.35% |
| Gross margin | 86.58% | 74.84% |
| Net margin | 40.61% | 7.35% |
| Revenue CAGR 5y | 17.22% | 15.32% |
| EPS CAGR 5y | 29.84% | - |
| Debt / Equity | - | 0.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- Debt / Equity-vs 0.3x+100%
- Market cap$24.13Bvs $1.77B+93%
- EV/EBIT15.2xvs 159.9x+90%
- ROIC (TTM)18.81%vs 3.35%+82%
VCEL leads on
No clear edges - the other side wins or ties on every measured metric.
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.